Ligand (LGND) Q2 Revenue Jumps 15%
Ligand Pharmaceuticals (NASDAQ:LGND), a biopharma company known for earning royalties from a broad portfolio of drugs, announced results for the second quarter of 2025 on August 7, 2025. The company exceeded analyst estimates with non-GAAP EPS of $1.60 (consensus: $1.42) and reported revenue of $47.6 million (consensus: $43.87 million) for the second quarter. The results showed robust revenue growth, especially from royalties, prompting an upgrade to its full-year 2025 guidance. Overall, the period was highlighted by standout royalty contributions, continued investment in late-stage assets, and confident management outlook despite higher operating expenses.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Ligand Pharmaceuticals operates a unique model in the biotech sector. Rather than developing drugs itself, it invests in or acquires royalty and milestone rights to drugs being marketed by its partners. Its revenue base is built from dozens of commercial and late-stage assets, generating consistent income from royalties, licensing, proprietary technology platforms, and stakes in drug sales.
Source Fool.com
